RestorGenex Corp. (OTCQB: RESX) is a specialty biopharmaceutical company focused on the development of a portfolio of first-in-class therapeutic products to treat diseases across the oncologic, ophthalmologic and dermatologic space. The company’s lead product is a novel PI3K/Akt/mTOR pathway inhibitor which has completed two phase I clinical trials for age-related macular degeneration and is in pre-clinical development for glioblastoma multiforme. RestorGenex’s current pipeline also includes a soft anti-androgen compound for the treatment of acne vulgaris. For more information, visit the company’s website at www.restorgenex.com.